Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 20-Hydroxyecdysone SCHEMBL20033388 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL9481370 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8193574 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL6243068 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8193572 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL22087 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8861138 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL17580332 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL8861142 | 1.00 | MEN1 (0.71) | MEN1KMT2A | |
| 20-Hydroxyecdysone SCHEMBL3043993 | 1.00 | MEN1 (0.71) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968290-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015161283-A1 | TRICYCLIC LACTAMS FOR USE IN HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2015161285-A1 | TRICYCLIC LACTAMS FOR USE IN THE PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2015161288-A1 | TRICYCLIC LACTAMS FOR USE AS ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2015161287-A1 | TRICYCLIC LACTAMS FOR USE IN THE PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| EP-2831080-A1 | LACTAM KINASE INHIBITORS | Tavares, Francis Xavier (US) | 2015-02-04 | — | — | EP | claimed |
| WO-2014144326-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| WO-2013148748-A1 | LACTAM KINASE INHIBITORS | TAVARES FRANCIS XAVIER (US) | 2013-10-03 | — | — | WO | claimed |
| EP-2632467-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | claimed |
| EP-0740930-A1 | BLOOD FLOW IMPROVER AND COSMETIC | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1996-11-06 | — | — | EP | claimed |
| EP-3253399-B1 | COMPOSITIONS AND METHODS FOR IMPROVED MUSCLE METABOLISM | NATUREX SA (FR) | 2021-10-13 | — | — | EP | disclosed |
| EP-3653209-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 Therapeutics, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10258658-B2 | Compositions and methods for improved muscle metabolism | NATUREX SA (FR) | 2019-04-16 | — | — | US | disclosed |
| US-20170296605-A1 | COMPOSITIONS AND METHODS FOR IMPROVED MUSCLE METABOLISM | NATUREX SA (FR) | 2017-10-19 | — | — | US | disclosed |
| US-20110021474-A1 | Ecdysterone Compounds | THERMOLIFE INTERNATIONAL, LLC | 2011-01-27 | — | — | US | disclosed |
| US-20050191385-A1 | Natural product derivatives as food supplements and pharmaceuticals | AMATO DANIEL K (US) | 2005-09-01 | — | — | US | disclosed |
| EP-0740930-B1 | BLOOD FLOW IMPROVER AND COSMETIC | POLA CHEM IND INC (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-5976515-A | POLYPORESTERONE A | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0740930-A1 | BLOOD FLOW IMPROVER AND COSMETIC | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1996-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050191385-A1 | Natural product derivatives as food supplements and pharmaceuticals | NGLY1, FABP6, VIP | MEN1 1503/4885KMT2A 4421/4885 |
| US-20110021474-A1 | Ecdysterone Compounds | SEC16A, EEF2K, SEC22B | MEN1 2719/4885KMT2A 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.